FINAL RESULT OF THE SUBSEQUENT OFFERING

Reference is made to the stock exchange notice dated 3 November 2010 and
the prospectus dated 2 November 2010 regarding a subsequent offering of
up to 60,000,000 offer shares in DiaGenic ASA ("DiaGenic" or the
"Company"), each with a nominal value of NOK 0.05, at a subscription
price of NOK 0.50 per share with subscription rights for shareholders of
the Company as of 6 October 2010, except shareholders who were allocated
shares in the private placement completed on 6 October 2010.

The subscription period in the subsequent offering in DiaGenic expired
at 17:30 (CET) on 17 November 2010. At the end of the subscription
period, DiaGenic had received subscriptions for a total of 94,406,689
new shares. Consequently, the subsequent offering was oversubscribed by
approximately 57.3 per cent.

Approximately 50.9 per cent of the subscribed new shares (approximately
48.0 million shares) were subscribed by exercising subscription rights.
Approximately 49.1per cent of the subscribed new shares (approximately
46.4 million shares) were subscribed for through oversubscription by
holders of subscription rights or by subscribers without subscription
rights.

In a board meeting 23 November 2010, the Board of Directors of DiaGenic
approved the final allocation of the shares offered in the subsequent
offering based on the allocation criteria set out in the prospectus
dated 2 November 2010. A total of 60,000,000 new shares have been
allocated. Approximately 48.0 million new shares have been allocated to
subscribers on the basis of exercised subscription rights. Approximately
12.0 million new shares have been allocated to holders of subscription
rights on basis of oversubscription. No allocation has been made to
subscribers without subscription rights.

Letters of notification of new shares allocated and the corresponding
subscription amount to be paid by each subscriber are expected to be
distributed on 23 November 2010. Payment for the allocated shares falls
due on 26 November 2010 in accordance with the payment procedures
described in the prospectus.

The new shares may not be transferred or traded before they are fully
paid and the share capital increase pertaining to the subsequent
offering has been registered with the Norwegian Register of Business
Enterprises. It is expected that the share capital increase will be
registered in the Norwegian Register of Business Enterprises on or about
6 December 2010 and that the new shares will be admitted to trading on
the Oslo Stock Exchange on the same day.

Through the subsequent offering, DiaGenic will receive proceeds of NOK
30,000,000 before the deduction of transaction costs. Following
registration of the share capital increase in the Norwegian Register of
Business Enterprises, the Company's share capital will be NOK 13,511,826
divided into 270,236,520 shares, each with a nominal value of NOK 0.05.

DnB NOR Markets acted as manager in the subsequent offering.

Contact:

Erik Christensen, CEO

Telephone: 47 95939918

e-mail: erik.christensen@diagenic.com